Drug Profile
BMS 866949
Alternative Names: BMS-866949Latest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator AMRI
- Developer Curia
- Class Antidepressants
- Mechanism of Action Biogenic amine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Sweden (PO)
- 26 Mar 2012 Bristol-Myers Squibb terminates a phase I trial in volunteers in Sweden (NCT01124344)
- 31 Jul 2009 Phase-I clinical trials in Major depressive disorder in Sweden (PO)